Jill S. Whyte

Jill S. Whyte

Oncology
9 Vermont Drive
1st Floor
New Hyde Park, NY 11042

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 13 publications

Expanded subtype testing for circulating tumor HPV DNA reliably detects the presence of advanced-stage cervical cancer.

Expanded subtype testing for circulating tumor HPV DNA reliably detects the presence of advanced-stage cervical cancer.

Journal: Gynecologic oncology
Published: January 19, 2026

Multicenter dose de-escalation phase I trial of pressurized intraperitoneal aerosolized chemotherapy (PIPAC) nab-paclitaxel and cisplatin in combination with systemic nab-paclitaxel in recurrent ovarian cancer patients: trial in progress.

Multicenter dose de-escalation phase I trial of pressurized intraperitoneal aerosolized chemotherapy (PIPAC) nab-paclitaxel and cisplatin in combination with systemic nab-paclitaxel in recurrent ovarian cancer patients: trial in progress.

Journal: Pleura and peritoneum
Published: September 25, 2025

Percutaneous transesophageal gastrostomy in gynecologic oncology patients with symptomatic malignant bowel obstruction: A case series.

Percutaneous transesophageal gastrostomy in gynecologic oncology patients with symptomatic malignant bowel obstruction: A case series.

Journal: Gynecologic oncology reports
Published: July 25, 2025

Maintenance with niraparib in patients with stage III, stage IV, chemo-naïve recurrent or platinum-sensitive recurrent uterine serous carcinoma: study protocol for a phase II clinical trial.

Maintenance with niraparib in patients with stage III, stage IV, chemo-naïve recurrent or platinum-sensitive recurrent uterine serous carcinoma: study protocol for a phase II clinical trial.

Journal: BMJ open
Published: June 05, 2025

Addition of metronidazole to standard-of-care perioperative prophylaxis at the time of hysterectomy for gynecologic malignancies.

Addition of metronidazole to standard-of-care perioperative prophylaxis at the time of hysterectomy for gynecologic malignancies.

Journal: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
Published: June 04, 2025

Adenoid basal cell carcinoma: An underrecognized cervical malignancy.

Adenoid basal cell carcinoma: An underrecognized cervical malignancy.

Journal: Gynecologic oncology reports
Published: November 06, 2024

Adherence to risk-reducing salpingo-oophorectomy guidelines among gynecologic oncologists compared to general gynecologists.

Adherence to risk-reducing salpingo-oophorectomy guidelines among gynecologic oncologists compared to general gynecologists.

Journal: American journal of obstetrics and gynecology
Published: February 27, 2023

Anti-NMDA receptor encephalitis with neurologic sequelae refractory to conservative therapy with complete response to adjuvant therapy.

Anti-NMDA receptor encephalitis with neurologic sequelae refractory to conservative therapy with complete response to adjuvant therapy.

Journal: Gynecologic oncology reports
Published: April 22, 2020

Overall Survival and Adjuvant Therapy in Women with Ovarian Carcinosarcoma: A Single-Institution Experience.

Overall Survival and Adjuvant Therapy in Women with Ovarian Carcinosarcoma: A Single-Institution Experience.

Journal: Diagnostics (Basel, Switzerland)
Published: October 23, 2019

Correction: Identification of grade and origin specific cell populations in serous epithelial ovarian cancer by single cell RNA-seq.

Correction: Identification of grade and origin specific cell populations in serous epithelial ovarian cancer by single cell RNA-seq.

Journal: PloS one
Published: December 05, 2018

Identification of grade and origin specific cell populations in serous epithelial ovarian cancer by single cell RNA-seq.

Identification of grade and origin specific cell populations in serous epithelial ovarian cancer by single cell RNA-seq.

Journal: PloS one
Published: August 21, 2018

Two microRNA signatures for malignancy and immune infiltration predict overall survival in advanced epithelial ovarian cancer.

Two microRNA signatures for malignancy and immune infiltration predict overall survival in advanced epithelial ovarian cancer.

Journal: Journal of investigative medicine : the official publication of the American Federation for Clinical Research
Published: May 20, 2017
Showing 1-12 of 13

Last Updated: 09/26/2026